Heather Callender-Potters, Co-Founder, Vice-Chairman and Chief Advocacy and Shareholder Relations Officer, PharmaJet
Heather Callender-Potters is Co-Founder, Vice-Chairman and Chief Advocacy and Shareholder Relations Officer of PharmaJet, a needle-free jet injection technology focused on immunizations. Having spent more than a decade to develop the company’s technology, including clinical testing, regulatory achievements, and commercial scaling for wide-spread use of the technology, PharmaJet currently enjoys 60 collaboration relationships across 140 distinct vaccine and therapeutic development programs. Partners span the globe, and include pharmaceutical companies, governments, universities, and NGO’s.
The original vision of focusing on immunization to help improve people’s lives and contribute to world health through the elimination of needle-based risks and inefficiencies, PharmaJet is the first and only WHO prequalified needle-free technology, among numerous other regulatory approvals (FDA, CE Mark, and multiple countries). PharmaJet also uniquely plays a role in the Global Polio Eradication Initiative, where clinical studies conducted by the World Health Organization have proven that its intradermal technology generates a superior immune response using 60% less vaccine. During the past year of the pandemic, PharmaJet has established several COVID vaccine collaborations, and currently is scaling its manufacturing to support the Zydus Cadila Plasmid DNA vaccine candidate in India.
Underlying Heather’s involvement with PharmaJet, she has ~30 years of Private Equity fund management and international investment experience across multiple jurisdictions. Her investment career started in 1991 when she moved to Poland as part of the Enterprise Fund concept championed by President Bush, Sr. Over time, she spent 19 years investing three funds, covering Central and Eastern Europe, and managing individual investments and financial investor consortiums, in early stage and growth companies, ranging from $1 million to an excess of $100 million, in a variety of industries. She returned to the US in 2010 to focus on PharmaJet’s development, she has continued as an active board member and/or angel investor in certain other companies with the ability to make a profound impact in health. Underlying her practical experience, she has a Bachelor of Arts degree in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania.